BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7989759)

  • 1. Octamer factors exert a dual effect on the IL-2 and IL-4 promoters.
    Pfeuffer I; Klein-Hessling S; Heinfling A; Chuvpilo S; Escher C; Brabletz T; Hentsch B; Schwarzenbach H; Matthias P; Serfling E
    J Immunol; 1994 Dec; 153(12):5572-85. PubMed ID: 7989759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th2-specific protein/DNA interactions at the proximal nuclear factor-AT site contribute to the functional activity of the human IL-4 promoter.
    Li-Weber M; Salgame P; Hu C; Davydov IV; Laur O; Klevenz S; Krammer PH
    J Immunol; 1998 Aug; 161(3):1380-9. PubMed ID: 9686601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octamer proteins inhibit IL-4 gene transcription in normal human CD4 T cells.
    Cron RQ; Zhou B; Brunvand MW; Lewis DB
    Genes Immun; 2001 Dec; 2(8):464-8. PubMed ID: 11781715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C/EBPbeta enhances IL-4 but impairs IL-2 and IFN-gamma induction in T cells.
    Berberich-Siebelt F; Klein-Hessling S; Hepping N; Santner-Nanan B; Lindemann D; Schimpl A; Berberich I; Serfling E
    Eur J Immunol; 2000 Sep; 30(9):2576-85. PubMed ID: 11009091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E2 inhibits the nuclear transcription of the human interleukin 2, but not the Il-4, gene in human T cells by targeting transcription factors AP-1 and NF-AT.
    Paliogianni F; Boumpas DT
    Cell Immunol; 1996 Jul; 171(1):95-101. PubMed ID: 8660843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic AMP inhibits expression of the IL-2 gene through the nuclear factor of activated T cells (NF-AT) site, and transfection of NF-AT cDNAs abrogates the sensitivity of EL-4 cells to cyclic AMP.
    Tsuruta L; Lee HJ; Masuda ES; Koyano-Nakagawa N; Arai N; Arai K; Yokota T
    J Immunol; 1995 May; 154(10):5255-64. PubMed ID: 7730629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT.
    Paliogianni F; Raptis A; Ahuja SS; Najjar SM; Boumpas DT
    J Clin Invest; 1993 Apr; 91(4):1481-9. PubMed ID: 8473495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B.
    Mouzaki A; Serfling E; Zubler RH
    Eur J Immunol; 1995 Aug; 25(8):2177-82. PubMed ID: 7664781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublethal levels of oxidative stress stimulate transcriptional activation of c-jun and suppress IL-2 promoter activation in Jurkat T cells.
    Beiqing L; Chen M; Whisler RL
    J Immunol; 1996 Jul; 157(1):160-9. PubMed ID: 8683110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin E2 inhibits the interleukin-2 promoter activity through down-regulation of the Oct-dependent transcription of the octamer motif.
    Felli MP; Moschella C; Farina AR; Alesse E; Screpanti I; Teti D; Frati L; Gulino A
    Cell Immunol; 1996 Sep; 172(2):229-34. PubMed ID: 8964085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal regulation of the IL-2 promoter in lpr CD4-CD8- T lymphocytes results in constitutive expression of a novel nuclear factor of activated T cells-binding factor.
    Clements JL; Cooper SM; Budd RC
    J Immunol; 1995 Jun; 154(12):6372-81. PubMed ID: 7759875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of P5, a novel NFAT/AP-1 site in the human IL-4 promoter.
    Burke TF; Casolaro V; Georas SN
    Biochem Biophys Res Commun; 2000 Apr; 270(3):1016-23. PubMed ID: 10772943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of transcription directed by a discrete NF-AT binding element from the IL-4 promoter in naive and effector CD4 T cells.
    Aune TM; Flavell RA
    J Immunol; 1997 Jul; 159(1):36-43. PubMed ID: 9200436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction and functional interference of C/EBPbeta with octamer factors in immunoglobulin gene transcription.
    Hatada EN; Chen-Kiang S; Scheidereit C
    Eur J Immunol; 2000 Jan; 30(1):174-84. PubMed ID: 10602039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification of the 120 kDa component of the human nuclear factor of activated T cells (NF-AT): reconstitution of binding activity to the cis-acting element of the GM-CSF and IL-2 promoter with AP-1.
    Tokumitsu H; Masuda ES; Tsuboi A; Arai K; Arai N
    Biochem Biophys Res Commun; 1993 Oct; 196(2):737-44. PubMed ID: 8240350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An NF-kappa B-like element plays an essential role in interleukin-1-mediated costimulation of the mouse interleukin-2 promoter.
    Stricker K; Serfling E; Krammer PH; Falk W
    Eur J Immunol; 1993 Jul; 23(7):1475-80. PubMed ID: 8325323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the AP-1 sites in the IL-2 promoter.
    Jain J; Valge-Archer VE; Rao A
    J Immunol; 1992 Feb; 148(4):1240-50. PubMed ID: 1737937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta-opioid receptors expressed by Jurkat T cells enhance IL-2 secretion by increasing AP-1 complexes and activity of the NF-AT/AP-1-binding promoter element.
    Hedin KE; Bell MP; Kalli KR; Huntoon CJ; Sharp BM; McKean DJ
    J Immunol; 1997 Dec; 159(11):5431-40. PubMed ID: 9548483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings.
    Feske S; Müller JM; Graf D; Kroczek RA; Dräger R; Niemeyer C; Baeuerle PA; Peter HH; Schlesier M
    Eur J Immunol; 1996 Sep; 26(9):2119-26. PubMed ID: 8814256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor-beta 1 (TGF-beta1) promotes IL-2 mRNA expression through the up-regulation of NF-kappaB, AP-1 and NF-AT in EL4 cells.
    Han SH; Yea SS; Jeon YJ; Yang KH; Kaminski NE
    J Pharmacol Exp Ther; 1998 Dec; 287(3):1105-12. PubMed ID: 9864299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.